MURA: Mural Oncology plc Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 58.93
Enterprise Value ($M) -52.09
Book Value ($M) 174.14
Book Value / Share 10.20
Price / Book 0.34
NCAV ($M) 154.66
NCAV / Share 9.05
Price / NCAV 0.38

Profitability (mra)
Return on Invested Capital (ROIC) -0.84
Return on Assets (ROA) -5.09
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 7.38
Current Ratio 7.38

Balance Sheet (mrq) ($M)
Current Assets 183.79
Assets 203.27
Liabilities 29.13
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
5 days ago 13G/A Armistice Capital, Llc 9.98 2.53
7 days ago 13G/A Vanguard Group Inc 4.90 0.00
08-05 13G/A Westfield Capital Management Co Lp 0.00 -100.00
07-08 13G/A BlackRock, Inc. 2.00 -70.79

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-03-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-12-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-18 5,045 41,539 12.15
2024-11-15 41,326 172,236 23.99
2024-11-14 22,591 91,034 24.82
2024-11-13 9,660 63,081 15.31

(click for more detail)

Similar Companies
MNOV – MediciNova, Inc. MRNS – Marinus Pharmaceuticals, Inc.
MRUS – Merus N.V. NAII – Natural Alternatives International, Inc.
NAMS – NewAmsterdam Pharma Company N.V.


Financial data and stock pages provided by
Fintel.io